The FDA has released a draft guidance outlining how drug developers can validate new approach methodologies (NAMs) as alternatives to animal testing in preclinical drug development. The guidance, ...
Morning Overview on MSN
FDA urges alternatives to animal testing in early-stage drug development
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...
FDA’s NAM framework emphasizes context of use, human biological relevance, technical characterization, and fit-for-purpose ...
MedPage Today on MSN
FDA Proposes More Flexibility in Alternatives to Animal Testing in Drug Development
Non-animal testing methods could save drugmakers time and money, officials say ...
Cell and gene therapies require novel quality control methods due to their complex, variable nature and limited shelf life, challenging traditional pharmaceutical testing approaches. Manufacturers ...
現在アクセス不可の可能性がある結果が表示されています。
アクセス不可の結果を非表示にする